– Double-digit organic growth in constant currency
– EBITDA Margin less capitalized development cost > 10%
– NET DEBT / EBITDA <3.0x
The new financial targets are designed to support self-financed profitable growth and our Vision 2030 – Be the world’s leading laboratory automation company for treatment development application by 2030
Financial targets framework
– Valid from 2023 on a mid-term basis.
– Growth target captures market growth opportunities.
– Margin target secures focus on profitability including total R&D spending and enables positive cash flow excluding acquisition-related items.
– Net Debt target enables flexibility in future financing alternatives.